Skip to main content

Table 4 Comparison of the serological findings between patients experiencing an adverse reaction (AR) to immunotherapy and those without complications (NC)

From: Anaphylactic reactions in the build-up phase of rush immunotherapy for bee venom allergy in pediatric patients: a single-center experience

  All patients AR NC  
No. of patients 19 3 16 P
sIgE honey bee venom [kU/l] m (± SD) (n = 19)
38.1 (± 36.3)
(n = 3)
82.7 (± 15.3)
(n = 16)
29.7 (± 14.0)
0.019*
Api m1 [kU/l] m (± SD) (n = 17)
13.8 (± 24.3)
(n = 3)
29.3 (± 10.2)
(n = 14)
10.5 (± 14.0)
0.253
Api m3 [kU/l] m (± SD) (n = 16)
8.4 (± 7.9)
(n = 2)
22.3 (± 1.9)
(n = 14)
6.4 (± 8.9)
0.005**
Api m10 [kU/l] m (± SD) (n = 18)
20.2 (± 33.5)
(n = 3)
38.6 (± 43.5)
(n = 15)
16.5 (± 35.1)
0.326
Serum tryptase [μg/l] m (± SD) (n = 14)
3.6 (± 2.6)
(n = 1)
6.2 (± 0)
(n = 13)
3.4 (± 2.2)
0.348
  1. For the different groups the respective averages, the minimum, the maximum and the standard deviation for total IgE, Api m1, Api m3, Api m10 are indicated. The units are indicated in square brackets. *p < 0.05, **p < 0.01, ***p < 0.001
  2. AR patients experiencing an adverse reaction to immunotherapy, NC patients undergoing immunotherapy without complications, No. number, SD standard deviation, m mean